Trump announces 100% chip tariff as Apple ups U.S. investment
Investing.com - Lucid Diagnostics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Lucid Diagnostics announced earnings per share of $-0.28 on revenue of $76K. Analysts polled by Investing.com EPS of $-0.35 on revenue of $431.38K.
Lucid Diagnostics 's are down 30% and is trading at $2.27 , still down 79.17% from its 52 week high of $10.90 set on Tuesday, November 16, 2021.
Lucid Diagnostics follows other major Healthcare sector earnings this month
Lucid Diagnostics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar